Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 253

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 8
Chunk 253
---
, if the lawsuit is certified as a class action, as set forth in the motion is approximately NIS 113.5 million (approximately $32
million). On December 10, 2024, the Tel Aviv District Court (Economic Division) granted an order to dismiss the claim.

Biokine
Claim

On June 16, 2024, Biokine filed
a complaint with the District Court of Jerusalem against us. The complaint alleges breach of contract and a purported failure to make
certain payments to Biokine under our in-licensing agreement with Biokine for motixafortide. The lawsuit seeks compensatory damages in
the amount of approximately $6.5 million and a declaratory judgment in favor of Biokine. We filed a statement of defense on November
17, 2024. We believe the claim is without merit and intend to vigorously defend ourselves against such action. On November 20, 2024,
we and Biokine entered into an agreement to refer the dispute to arbitration.

91

Dividend Distributions

We have never declared or paid cash dividends to our shareholders.
Currently we do not intend to pay cash dividends. We currently intend to reinvest any future earnings in developing and expanding our
business. Any future determination relating to our dividend policy will be at the discretion of our board of directors and will depend
on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions, capital requirements,
business prospects, applicable Israeli law and other factors our board of directors may deem relevant. Israeli law limits the distribution
of cash dividends to the greater of retained earnings or earnings generated over the two most recent years (referred to as the “profit
test”), in either case provided that we reasonably believe that the dividend will not render us unable to meet our existing and
foreseeable obligations when due (referred to as the “solvency test”). Notwithstanding the foregoing, in the event that
a company does meet the profit test, dividends may be paid with the approval of a court, provided that the court is convinced that the
company meets the solvency test. However, in accordance with the Relief Regulations, as a company whose shares are dual listed on
the TASE and a foreign exchange referenced in the second or third addendum to the Israeli Securities Law (which include, among others,
the Nasdaq), our board of directors may resolve to distribute a dividend by way of a share repurchase program (buy